.png)
Mid-size Bipharmaceutical
Market Access, HEOR, Medical Affairs
Pre-Launch
Rare Disease
Subscribe to our newsletter to receive the latest case studies.
Mid-size Bipharmaceutical
Market Access, HEOR, Medical Affairs
Pre-Launch
Rare Disease
A mid-size biopharmaceutical company was preparing to launch a rare disease therapy across multiple European markets.
Value communication was complicated by variable symptom severity, limited comparative evidence, and payer scrutiny of surrogate endpoints.
The client engaged Alkemi to test and refine the payer value story, anticipate objections, and define a market-specific access and evidence strategy to support EU HTA and reimbursement discussions.
1. Assessed rare disease analogues to identify successful tactics for communicating surrogate endpoint value.
2. Interviewed local affiliate market access leaders to understand country-specific payer expectations and HTA dynamics.
3. Conducted payer and KOL advisory boards to pressure-test value messages, validate credibility, and surface anticipated objections.
4. Developed market-specific value stories aligned to local evidence thresholds and decision drivers.
5. Defined longer-term evidence priorities to strengthen payer confidence over time.
Translate complex evidence into messages that hold up across EU markets.
“Alkemi helped us pressure-test our value narrative and translate complex evidence into messages that resonated with payers.” - Global HEOR Lead
Improved understanding of payer perceptions, evidence thresholds, and decision drivers across markets.
Market-specific value stories addressed anticipated objections and strengthened HTA readiness.
Identified long-term strategies to build confidence, including registries, access schemes, and disease studies.